Genitourinary Cancer Clinical Trials

A listing of Genitourinary Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA)

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

clot
dalteparin
embolism
pulmonary embolism
thrombosis
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)

combination therapy will be further evaluated in tumor-specific Expansion Cohorts, which will enroll subjects with genitourinary cancers.

systemic therapy
carcinoma
karnofsky performance status
transitional cell carcinoma
metastatic renal cell carcinoma
  • 0 views
  • 17 Oct, 2022
  • 6 locations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). …

metastatic cervical cancer
erbb2
breast cancer
systemic therapy
trastuzumab
  • 27 views
  • 27 Oct, 2022
  • 61 locations
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

cancer
bone metastases
adenocarcinoma
  • 1 views
  • 22 Oct, 2022
  • 126 locations
Parametric PET of Genitourinary Cancer

Metastatic kidney cancer is usually treated with targeted therapy or immunotherapy which is costly and has low response rate. The current standard care is to perform anatomical imaging studies after a few cycles (months) of treatment to evaluate response. This approach exposes many patients to highly toxic, high expensive treatment …

targeted therapy
hysterectomy
pazopanib
sunitinib
oophorectomy
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. …

ct scan
lipase
tumor cells
kinase inhibitor
tubal ligation
  • 351 views
  • 27 Oct, 2022
  • 171 locations
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendocrine differentiation. Given preliminary results, the study is being tested in …

tumor cells
tubal ligation
carcinoma
hysterectomy
adenocarcinoma of the prostate
  • 83 views
  • 04 Oct, 2022
  • 6 locations
Atezolizumab in Patients With Urinary Tract Squamous Cell Carcinoma: a Single Arm, Open Label, Multicentre, Phase II Clinical Trial (AURORA)

Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial

squamous cell carcinoma
cancer
chemotherapy regimen
neutrophil count
measurable disease
  • 0 views
  • 23 Oct, 2022
  • 1 location
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

  • 0 views
  • 04 Oct, 2022
  • 1 location
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease (RADIANT)

genito-urinary cancer patients with oligo-progression. Patients will be seen before and at the end of treatment and will be followed at 4 month intervals for up to 2 years. During the visits

breast cancer
carcinoma
metastasis
primary cancer
docetaxel
  • 0 views
  • 24 Oct, 2022
  • 1 location